Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for neurological disorders. The company is engaged in developing tildacerfont, a non-steroidal therapy designed to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). This therapy is currently in Phase 2b clinical trials to evaluate glucocorticoid reduction in adult patients with classic CAH. Additionally, the company is developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children, which is in Phase 2 clinical trials. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses, as well as a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.